特发性/免疫相关疾病与常见直接危险因素所致ARDS的凝血病及肺泡上皮损伤生物标志物谱
该回顾性观察研究纳入87例无间接危险因素的ARDS成人患者,其中56例为直接常见危险因素相关ARDS(dARDS),31例为特发性/免疫相关疾病相关ARDS(iARDS)。iARDS患者中凝血酶生成标志物TAT和纤溶抑制标志物PAI-1升高,PC活性高于正常;而dARDS患者PC活性显著降低,TAT和PAI-1水平远高于iARDS患者。PCT、SP-D和KL-6在两组间也存在显著差异。ROC分析显示PC活性、PAI-1、PCT、SP-D和KL-6区分dARDS与iARDS的曲线下面积相似且均较高(PC 0.86、PAI-1 0.89、PCT 0.89、SP-D 0.88、KL-6 0.90)。作者认为这些生物标志物的不同模式可能有助于区分这两种ARDS亚型。
要点
- 在无间接危险因素的ARDS患者中,iARDS组TAT和PAI-1升高、PC活性高于正常,而dARDS组PC活性显著降低、TAT和PAI-1水平远高于iARDS组。
- PCT、SP-D和KL-6在dARDS与iARDS患者间存在显著差异。
- ROC分析显示PC活性、PAI-1、PCT、SP-D和KL-6区分dARDS与iARDS的曲线下面积相似且均较高:PC 0.86、PAI-1 0.89、PCT 0.89、SP-D 0.88、KL-6 0.90。
- 作者认为PAI-1、PC活性、SP-D和KL-6的不同模式可能有助于区分这两种ARDS亚型。
适用人群与场景
- 纳入成人ARDS患者,诊断依据柏林定义,且无间接危险因素,收住大学医院ICU。
- 排除标准:符合排除标准者(n=41)或因其他原因导致ARDS者(n=10)。
- 最终分析87例,其中dARDS 56例,iARDS 31例。
研究设计与关键结果
- 研究类型:回顾性观察研究;样本量:最终纳入87例ARDS患者(dARDS 56例,iARDS 31例);人群:无间接危险因素的成人ARDS患者;干预/暴露:ICU入住前5天内常规测量血浆生物标志物(TAT、PAI-1、PC活性、PCT、SP-D、KL-6)。
- iARDS患者中TAT和PAI-1升高,PC活性高于正常;dARDS患者PC活性显著降低,TAT和PAI-1水平远高于iARDS患者。
- PCT、SP-D和KL-6在dARDS与iARDS患者间存在显著差异。
- ROC分析区分dARDS与iARDS的曲线下面积:PC活性0.86(P=0.33)、PAI-1 0.89(P=0.95)、PCT 0.89(P=0.66)、SP-D 0.88(P=0.16)vs KL-6 0.90。
证据类型、等级与局限
- 证据类型:回顾性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,PAI-1、PC活性、SP-D和KL-6的不同模式可能有助于区分dARDS与iARDS亚型。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Altered coagulation and alveolar injury are the hallmarks of acute respiratory distress syndrome (ARDS). However, whether the biomarkers that reflect pathophysiology differ depending on the etiology of ARDS has not been examined. This study aimed to investigate the biomarker profiles of coagulopathy and alveolar epithelial injury in two subtypes of ARDS: patients with direct common risk factors (dARDS) and those with idiopathic or immune-related diseases (iARDS), which are classified as "ARDS without common risk factors" based on the Berlin definition.
METHODS: This retrospective, observational study included adult patients who were admitted to the intensive care unit (ICU) at a university hospital with a diagnosis of ARDS with no indirect risk factors. Plasma biomarkers (thrombin-antithrombin complex [TAT], plasminogen activator inhibitor [PAI]-1, protein C [PC] activity, procalcitonin [PCT], surfactant protein [SP]-D, and KL-6) were routinely measured during the first 5 days of the patient's ICU stay.
RESULTS: Among 138 eligible patients with ARDS, 51 were excluded based on the exclusion criteria (n = 41) or other causes of ARDS (n = 10). Of the remaining 87 patients, 56 were identified as having dARDS and 31 as having iARDS. Among the iARDS patients, TAT (marker of thrombin generation) and PAI-1 (marker of inhibited fibrinolysis) were increased, and PC activity was above normal. In contrast, PC activity was significantly decreased, and TAT or PAI-1 was present at much higher levels in dARDS compared with iARDS patients. Significant differences were also observed in PCT, SP-D, and KL-6 between patients with dARDS and iARDS. The receiver operating characteristic (ROC) analysis showed that areas under the ROC curve for PC activity, PAI-1, PCT, SP-D, and KL-6 were similarly high for distinguishing between dARDS and iARDS (PC 0.86, P = 0.33; PAI-1 0.89, P = 0.95; PCT 0.89, P = 0.66; and SP-D 0.88, P = 0.16 vs. KL-6 0.90, respectively).
CONCLUSIONS: Coagulopathy and alveolar epithelial injury were observed in both patients with dARDS and with iARDS. However, their biomarker profiles were significantly different between the two groups. The different patterns of PAI-1, PC activity, SP-D, and KL-6 may help in differentiating between these ARDS subtypes.
参考来源
- Koyama K, Katayama S, Tonai K, et al. Biomarker profiles of coagulopathy and alveolar epithelial injury in acute respiratory distress syndrome with idiopathic/immune-related disease or common direct risk factors. Crit Care. 2019. PMID: 31426849. doi:10.1186/s13054-019-2559-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。